Expert Interview
Discussing Replimune's RP1 (vusolimogene oderparepvec) in Combination with Nivolumab for Advanced Melanoma Ahead of its April FDA PDUFA Date
Ticker(s): REPL, MRK, BMY, NVS, RHHBY, PFE, IOVAInstitution: Moffitt Cancer Center
- Chief Academic Officer and Director of Regional Therapies at Moffitt Cancer Center; Chair on the Department of Oncologic Sciences at University of South Florida Morsani College of Medicine; Professor of Surgery at University of South Florida Morsani College of Medicine
- Manages 20-35 patients with metastatic uveal melanoma
- Research and clinical interests include the regional therapy treatment of cutaneous melanoma, non-melanoma skin cancers and soft tissue sarcomas; Also the director of regional therapies in the cutaneous oncology department
How many patients do you see with advanced melanoma?
Added By: lilly_adminOn a scale of 1 to 10 (with 10 being ecstatic), how excited are you for RP1 (vusolimogene oderparepvec) in Combination with Nivolumab for Advanced Melanoma?
Added By: lilly_adminWhat is your level of confidence in RP1 obtaining FDA approval?
Added By: ben_adminWhere would RP1 fit into your treatment algorithm if approved?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
